Although the classical tumor evasion hypothesis associated with the CD95 loss in tumor cells remains valid, this immune selection might be counterbalanced by the induction of an NF-κB-driven pro-inflammatory response, which could activate the anti-tumor activity of NK cells that we observed in TNBCs (Qadir et al., 2021). The gene discussed is NFKB1; the disease is neoplasm.